Natco Pharma says USFDA inspection at Chennai facility ends with zero observations

In a regulatory filing, Natco Pharma announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Chennai, India, conducted during the period July 8–12, 2019".

from Moneycontrol Business News https://ift.tt/2ShuJt3